<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: The main objective of this study was to investigate the potential use of circulating microRNAs (miRNAs) as biomarkers of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, a leading cause of <z:hpo ids='HP_0011420'>death</z:hpo>, is curable if detected early </plain></SENT>
<SENT sid="2" pm="."><plain>There is an unmet need for an accurate, noninvasive biomarker of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>MiRNAs are non-protein-coding <z:chebi fb="40" ids="33697">RNAs</z:chebi> regulating gene expression that play a role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> development </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Levels of 380 miRNAs were determined using microfluidic array technology (Applied Biosystems) in a "training" set of 30 CRC patients from whom <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and adjacent <z:mpath ids='MPATH_458'>normal</z:mpath> tissue were collected </plain></SENT>
<SENT sid="5" pm="."><plain>The 4 most dysregulated miRNAs (P &lt; 0.05, false discovery rate (FDR): 10%) were then validated in a second blinded "test" set of 16 CRC patients from whom <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> adjacent tissue had been collected </plain></SENT>
<SENT sid="6" pm="."><plain>Validated tissue miRNAs were then evaluated in a plasma "test" set consisting of 30 CRC patients and 30 individuals without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The most dysregulated tissue miRNAs were then validated in an independent new plasma test set consisting of 20 CRC patients with 20 age-, -, and race-matched subjects without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Nineteen of 380 miRNAs were dysregulated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> tissue in the tissue "training" set (P &lt; 0.05, FDR: 10%) </plain></SENT>
<SENT sid="9" pm="."><plain>The 2 most upregulated (miR-31; miR-135b) and most downregulated (miR-1; miR-133a) miRNAs identified <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in our "test" set with 100% sensitivity and 80% specificity </plain></SENT>
<SENT sid="10" pm="."><plain>MiR-31 was more upregulated in stages III and IV compared with stages I and II (P &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>In the "plasma" group, miR-21 differentiated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients from controls with 90% specificity and sensitivity </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Plasma miRNAs provide reliable and noninvasive markers for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Plasma miR-21 warrants study in larger cohorts </plain></SENT>
<SENT sid="14" pm="."><plain>It seems uniquely promising as a plasma biomarker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>